Engene appoints joan connolly as chief technology officer and anthony cheung, ph.d., as chief scientific officer

Boston & montreal--(business wire)--engene holdings inc. (nasdaq: engn or “engene” or the “company”), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid (also known as detalimogene, and previously eg-70) is in an ongoing pivotal study in patients with high-risk, bacillus calmette-guÉrin (bcg)-unresponsive, non-muscle invasive bladder cancer (nmibc) with carcinoma in situ (cis), today announced the appointment of joan connolly as chie.
ENGN Ratings Summary
ENGN Quant Ranking